Abstract: Postpartum depression (PPD) is the most common unrecognized complication of childbirth and affects 1 out of 7 childbearing women. Although conventional pharmacologic and psychotherapeutic antidepressant treatments are effective for PPD, a natural alternative may be preferred by postpartum women, especially those who breastfeed their infants. The treatment of PPD with synthetic forms of naturally occurring estrogen is mechanistically appealing because PPD occurs in the context of estrogen withdrawal at parturition. Preliminary evidence suggests that PPD is a disorder of hormone-related mood dysregulation (similar to perimenopausal depression) that can be effectively treated with estrogen. This review provides the basic science and clinical background as well as safety considerations to support the application of transdermal estradiol as a treatment for PPD. We conclude that estradiol treatment for PPD requires confirmation of efficacy in a randomized clinical trial before routine clinical use as monotherapy. Additional data regarding maternal tolerability of cyclic progestins, long-term safety of estradiol treatment, estradiol passage into breast milk and infants, and interdisciplinary collaboration among psychiatrists and gynecologists is also needed before estradiol is used in women who decline or fail to respond to first-line antidepressant treatments, or as an augmentation of conventional antidepressant treatment.
Key words: postpartum depression, transdermal estradiol
Postpartum Depression-Its Public Health Impact, Treatment, and the Demand for Novel Therapeutics Postpartum depression (PPD) is a major public health concern (Healthy People 2010, Objective 16-5c 1 ). PPD (which includes both major and minor depression) affects at least 14.5% (1 out of 7) of women in their first 3 months postpartum 2 with rates that rise to 23% to 59% among inner-city 3 and adolescent mothers. 4 Suicide is a leading cause of death in new mothers, and suicidal thoughts and nonfatal self-harm behaviors are prevalent in this population. 5 The sequelae of PPD include not only maternal low mood and anxiety, 6, 7 but also deleterious effects of impaired maternal caregiving 8, 9 on child development. 10, 11 Randomized clinical trials (RCTs) have demonstrated that pharmacologic and psychotherapy antidepressant treatments are as effective for PPD [12] [13] [14] as they are for major depressive disorder that occurs in nonpostpartum women. 15 Nortriptyline and sertraline treatment of PPD were both associated with approximately 60% rates of response and 50% rates of remission. 14 Twelve-week interpersonal psychotherapy was associated with a 37.5% remission rate relative to 13.7% in the waiting list control group, 13 an index of efficacy that is similar to that demonstrated in nonpostpartum populations. 16 Replicated studies reveal negligible passage of sertraline, paroxetine, and nortriptyline into the sera of nursing infants, 17 thus making psychotropic treatment in PPD more widespread for breastfeeding mothers. These landmark clinical studies have demonstrated that conventional antidepressant treatments are effective for women with PPD.
Notwithstanding the progress made in PPD treatment, antidepressant remission rates of 30% to 50% in PPD and in major depressive disorder 18 leave a large void to be filled with novel treatments. Estradiol treatment is one such novel therapy that shows promise for the achievement of more rapid and higher rates of remission in PPD 19, 20 similar to what has been demonstrated in perimenopause-onset depression. 21, 22 The robust antidepressant effect of estradiol is putatively related to estradiol-mediated normalization of hormonally sensitive neural circuits of depression that are activated during PPD and other reproductive hormonerelated mood disorders. [23] [24] [25] In addition to being potentially more efficacious than conventional antidepressant treatment, estradiol might also be more acceptable to women with PPD who perceive that hormonal treatments more directly address the etiology of their disorder.
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Estradiol may also be regarded as a natural therapeutic that overcomes the stigma of conventional treatments. 26 Epidemiologic, Clinical Research, and Basic Science Evidence, Which Support Estradiol as a Therapeutic for PPD
Epidemiologic studies converge to powerfully suggest that female gonadal steroid fluctuations can lower the threshold for emergence of mood disorder symptoms and episodes. 27 This theory is substantiated by the 2-fold to 3.5-fold increase in risk for psychiatric hospitalization due to incident PPD in the 5 months after childbirth, 28 the 2-fold to 5-fold risk for major depressive episode and depressive symptoms in perimenopausal compared with premenopausal women, 29, 30 and the 1.7-fold increased risk for major depression in women relative to men during childbearing years that begins during puberty. 31, 32 Furthermore, susceptibility to depressed mood during 1 reproductive transition (ie, premenstrual dysphoric disorder) confers vulnerability for future reproductive hormone-related mood disorders. [33] [34] [35] As evidenced by hormone manipulation experiments, the ovarian hormones estradiol and progesterone are potent modulators of individual risk for reproductive hormone-related mood disorders. In women with premenstrual dysphoric disorder, mood symptoms remitted in 66% of women after ovarian suppression with the gonadotropin releasing hormone agonist leuprolide. Symptoms reemerged after add-back of estradiol and progesterone in concentrations that approximated the mid-luteal phase. 36 Similar findings emerged in a perinatal simulation study in which leuprolide-suppressed women were given and then withdrawn from estradiol doses that simulated peak menstru-al cycle concentrations and progesterone doses that simulated mid-gestation concentrations. Among women with a history of PPD, 63% experienced depressive symptom increase during addition of combined estradiol and progesterone which peaked during withdrawal of these hormones. 24 In both studies, women without reproductive hormone-related mood disorders experienced no significant mood symptoms during hormonal manipulation. These experiments point to important neuromodulatory effects of both estradiol and progesterone in vulnerable women. We focus on estradiol in this manuscript.
Estradiol seems to function as an antidepressant through mechanisms inherent in traditional psychotropics 37, 38 in widespread regions of the cortex and limbic brain. 39 Estradiol promotes neurite outgrowth and neuronal survival in hypothalamus, amygdala, hippocampus, dopaminergic neurons, and prefrontal cortex. 40 Pro-monoaminergic effects of estradiol include enhancement of norepinephrine, dopamine, 41 cholinergic, 42 and serotonin systems. [43] [44] [45] Estradiol also mitigates against oxidative stress, glutamateric excitotoxicity, and b-amyloid toxicity. 46 A potential role for estradiol to modulate feedback regulation of the hypothalamic-pituitary-adrenal axis 47 is yet another mechanism by which estradiol may act as a psychotropic.
Clinical Trials of Estradiol for the Treatment of PPD: Efficacy, Safety, and Future Directions
PPD is a disorder that is particularly wellsuited for estradiol treatment because it occurs after 100-fold decreases in ambient estradiol between late pregnancy and 48 hours postparturition. Two published trials suggest that PPD treatment response to estradiol (B80%) exceeds that of standard antidepressants (50.1% ± 9.0% 15 ). Gregoire et al 20 enrolled 61, nonbreastfeeding women who presented within 18 months of delivery. Subjects had severe depressive symptoms, reported as mean Edinburgh Postnatal Depression Screening Scale (EPDS) 48 score of 21.6 ± 3.0. The EPDS is a widely used screening scale for PPD in which scores of 10 or higher are highly sensitive for the presence of postpartum major depression. 48, 49 An EPDS score of 21 roughly corresponds to a Hamilton Rating Scale for Depression 17-item score of 28 (Wisner et al, unpublished) . Women were randomized to 6 months of treatment with placebo or high dose transdermal 17bestradiol (200 mcg/d). The mean estradiol concentration of actively treated women was 680 pmol/L (nearly twice the mean estradiol concentration across the menstrual cycle, which is B370 pmol/L). Within 1 month of treatment, EPDS scores of the estradiol-treated group were 4 points lower on average compared with the placebotreated group. Because assessments were done once a month, the time course of symptom improvement in the early weeks of treatment is unknown and may be substantially earlier. At 3 months of treatment, 80% of the estradiol group had EPDS scores <14, whereas only 31% of placebo group had scores <14 (corresponds to a Hamilton Rating Scale for Depression 17item score of <15) (Wisner et al, unpublished). By study completion (6 mo), EPDS scores in both groups had decreased; however, the EPDS scores for only the estradiol-treated subjects (score range, 6-9; 4.38 points lower than the placebo group) were consistent with resolution of the major depressive episode. 49, 50 Ahokas et al 19 treated 23 postpartum, severely depressed (mean Montgomery-Asberg Depression Rating Scale score; MADRS = 40) women who presented within 12 months of birth. Thirteen participants were breastfeeding. The women were hypogonadal (mean estradiol = 80 pmol/L) and half met criteria for gonadal failure. They were treated openly with sublingual 17b-estradiol (4.8 mg/d) for 8 weeks. The subjects' mean estradiol concentration by study completion rose to 478 pmol/L. Within a week of treatment, 21 of 23 subjects had 50% symptom score reductions and by 2 weeks, 19 of 23 (83%) subjects achieved remission (MADRS score r7). An inverse relationship between estradiol concentration and MADRS score was noted.
Estradiol treatment was well-tolerated in both studies as judged by low attrition. A suicide occurred in the randomized trial after estradiol was replaced with progesterone during a psychiatric hospitalization. 20 Women with contraindications to estradiol treatment, such as histories of thromboembolic events or uterine and breast disease were excluded, and no reports of adverse events were reported in the cited studies. During scheduled endometrial curettage at the study conclusion (6 mo), endometrial changes were found in 3 participants, despite coadministration of dydrogesterone (10 mg/d, 12 d/mo in the final 3 mo of the estradiol trial) [dydrogesterone (9Â , 10a-pregna-4, 6-diene-3, 20-dione) is an orally active progestogen with a molecular structure almost identical to that of natural progesterone], which resolved at follow-up. 20 Breast tenderness, headache, nausea and vomiting led to estradiol discontinuation in 3 of 6 women who were treated transdermally with 100 mcg/d in a study of nondepressed women. 51 In contrast, low attrition in the estradiol trials for depression suggests that depressed women may have fewer estradiol side effects than nondepressed women.
Although these studies support the treatment of PPD with estradiol, study design limitations weaken the evidence base for adding estradiol to the therapeutic armamentarium for PPD. In the randomized trial, the inclusion of women who took concurrent antidepressant medications (47% and 37% in the estradiol and placebo arms, respectively) limits the ability to discern an estradiol-specific Transdermal Estradiol for Postpartum Depression 519 treatment effect versus an augmentation effect. The EPDS is a self-report scale; the validity of the findings would be increased if they were confirmed with a clinician interview-based measure. The exclusion of breastfeeding women and the inclusion of severely depressed women (mean baseline EPDS = 21 which corresponds to a 17-item Hamilton Rating Scale for Depression Scale score of 28) but not women with mild or minor depression also limit the study's generalizability. In both studies, women who presented for treatment up to 12 to 18 months postpartum were included. This time frame is far removed from the estradiol withdrawal at delivery that theoretically contributes to PPD risk and is a primary rationale for estradiol treatment. Because epidemiologic and translational research 52,53 converge on an early postpartum timeframe for depression vulnerability, this might also be an ideal time to treat. Whether higher rates of estradiol treatment response and remission can be achieved in women with PPD onset proximal to delivery (ie, within a month postpartum) remains to be tested. Results of ongoing RCTs of estradiol for PPD (http://clinicaltrials.gov/ct2/ show/NCT00744328?term = wisner&rank = 4; http://www.clinicaltrials.gov/ct/show/ NCT00059228?order = 1) will buttress the evidence base for this potential therapy.
Selection of an Estrogen Formulation for PPD Treatment
Of fundamental importance is the fact that not all estrogens are alike. Estrogen types confer benefits and risks based upon their unique pharmacology and route of administration. Of the bioidentical estrogens, 17b-estradiol has greater estrogen receptor affinity relative to estrone and estriol. Transdermal 17b-estradiol administration closely resembles physiologic ovarian estradiol production because its metabolism results in a 1:1 ratio of estradiol to estrone concentrations. Conjugated equine estrogens, the most common form of estrogen therapy in menopausal women, are a biologic estrogen produced from the urine of pregnant mares. Conjugated equine estrogens contain up to 10 different estrogens, many of which possess higher affinity than estradiol for the estrogen receptor. The synthetic estrogen ethinyl estradiol differs from 17b-estradiol on the basis of an added ethinyl group at position C-17.
As a distinct compound than estradiol, ethinyl estradiol cannot be measured by estradiol assays and has no known bioequivalency to estradiol. Ethinyl estradiol has higher affinity for the estrogen receptor relative to 17b-estradiol. The potency and oral availability of ethinyl estradiol have made it the most widely used synthetic oral estrogen for contraception. All estrogens, except for transdermal 17bestradiol, are predominantly metabolized to the less potent, less lipophilic, and therefore less brain-available 54 estrogen, estrone sulfate. A critical pharmacologic advantage of transdermal estradiol delivery is that it bypasses the enterohepatic circulation. This route of delivery avoids induction of hepatic coagulation factors and triglyceride synthesis and therefore does not seem to increase risk for venothrombolic embolism. 55 In contrast, orally administered estradiol, ethinyl estradiol, and conjugated equine estrogens have the disadvantage of greater hepatic effects and increased venothrombolic embolism risk (odds ratio, 2-5). 56 Transdermal 17bestradiol has been advocated as the best available depression treatment in the puerperium and perimenopause because it most closely resembles physiologic ovarian estradiol production, it penetrates the brain the best, and it is not associated with venothromboembolic risk.
What Serum Concentration of Estradiol Is Therapeutic for PPD?
Estradiol concentrations achieved in transdermal estradiol treatment trials for perimenopause and PPD ranged from 260 to 700 pmol/L, which like menopausal hormone therapy, simulates mean menstrual cycle concentrations. Notably, such concentrations are 100-fold lower than late third trimester pregnancy estradiol concentrations (60,000 pmol/L). 57 Because no correlation between estradiol concentration and depression symptoms was observed in prior studies, 19, 20, 58 we lack evidence that higher estradiol concentrations more effectively treat depression. In addition, whether women with estradiol concentrations in the hypogonadal range (as occurs during lactational amenorrhea) stand to benefit more from estradiol treatment than nonhypogonadal women with PPD is an area of debate than deserves further study. 19, 58 In general, endogenous estradiol production is curtailed by exogenous estradiol negative feedback on gonadotropins. Therefore, the administered dose of estradiol translates directly into the serum concentration obtained. Pharmacokinetic studies of the Climara estradiol transdermal system indicated an approximate 1:1 ratio of administered estradiol concentration (in mcg) to serum estradiol concentration (pg/mL) obtained. Converted from picograms per milliliter to picomoles per liter (pmol/L), transdermal estradiol doses from 25 to 200 mcg/d roughly produce serum estradiol concentrations of 90 to 730 pmol/L. Interindividual and intraindividual variability in patch application compliance and estradiol absorption and metabolism yields a wide range of serum concentrations per dose administered. For example, among postmenopausal women, 50 mcg estradiol patches changed every 3 days (rather than twice per week 21 ) yielded higher serum concen-trations than 100 mcg patches changed twice weekly 22 (Table 1 ).
The 50 mcg estradiol patches changed every 3 days 21 also yielded nearly the same serum concentrations as 200 mcg estradiol patches changed twice weekly in postpartum women 20 (Table 1) . Research is needed to determine the lowest transdermal estradiol concentration that is efficacious for the treatment of depression and to examine how interindividual variability in estradiol metabolism moderates the estradiol dosetreatment response relationship.
Side Effects and Risks of Transdermal Estradiol
Common side effects of estrogen treatment include nausea, vomiting, bloating, stomach/abdominal cramps, headaches, migraines, changes in vaginal secretions, breast tenderness, episodes of vaginal bleeding and/or spotting, and hair loss. Other side effects include high blood pressure, edema, enlargement of uterine fibroids, and vaginal yeast infection. Oral estrogens are more commonly associated with hypertension and vaginal yeast infections. Transdermal estradiol formulations were well tolerated by postpartum and menopausal women with and without depression. [20] [21] [22] 51, 62, 65 Transdermal estradiol as dosed within the standard clinical range (r100 mcg/d) does not pose risk for venous thromboembolism. 56, 66 Whether supratherapeutic (>100 mcg/d) doses of transdermal estradiol confer thromboembolism risk is unknown. Doses up to 200 mcg/d have been used for the treatment of PPD without reported thromboembolic events. 20 Medical factors that warrant careful monitoring or withholding of high dose postpartum estradiol treatment include heavy smoking, a past thromboembolic event, thrombophlebitis, hypercoagulability or family history of such, untreated hyperlipidemia, uncontrolled hypertension, arterial vascular disease, heart disease, complicated migraine Transdermal Estradiol for Postpartum Depression 521 headaches, obesity (>35% ideal body weight), preeclapmsia, or eclampsia. 67, 68 Estradiol, like other hormones, can act like a carcinogen by increasing cell proliferation in target organs. Increases in cell divisions confer risk for random DNA copying errors and reduce time for repair of DNA damage, thus potentially result-ing in the propagation of genetic errors. Endometrial hyperplasia is a condition of endometrial cell proliferation that is commonly related to estrogen use in the absence of a progestin. This estrogen-related simple and nonatypical hyperplasia progresses to endometrial cancer in 1% of cases and is earlier in stage and lower in 
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Moses-Kolko et al grade relative to endometrial cancer in nonestrogen users. The risk of endometrial cancer posed by estrogen treatment in postpartum women is extremely low. Protective factors for endometrial hyperplasia in postpartum women include parity (wherein high progesterone production negates estrogen-induced hyperplasia), common use of progestin-containing intrauterine devices or progestin-only oral contraceptives, and lactational amenorrhea-associated hypoestrogenemia. Abnormal uterine bleeding may be a clinical sign of endometrial hyperplasia or cancer and should therefore invoke gynecologic evaluation with possible transvaginal ultrasound and endometrial biopsy. 69, 70 Progesterone administration for a minimum of 10 days every 3 months is required to prevent estrogen-related endometrial hyperplasia. 71 Progestin-releasing intrauterine devices are also highly effective for the prevention of endometrial hyperplasia. In women who develop endometrial hyperplasia, treatment consists of a 21day course of high dose progestin or endometrial ablation. Because 75% of breast cancers are estrogen receptor positive, both endogenous and exogenous estrogens can potentiate growth of such cancers. Nevertheless a large study found no increased risk of breast cancer in women with past or present oral contraceptive use, regardless of estrogen dose and duration of use. 72 This finding was also true for a subset of women with a positive first degree family history of breast cancer. Other studies conclude that exogenous estrogen-associated risk of breast cancer is at most 2% to 3% per year of use or 1-fold to 2-fold increased after 5 to 10 years of use. 73 More recent evidence suggests that long term, continuous coadministration of the progestin medroxyprogesterone acetate (with estrogen) confers additional risk for breast cancer. 74, 75 Epithelial-type ovarian cancer incidence is not heightened with exposure to reproductive hormones. In fact, parity and oral contraceptive use (clinical variables that suppress ovarian function) are protective factors for ovarian cancer.
Oral contraceptives that contained high dose oral ethinyl estradiol (50 mcg/d) were associated with new-onset liver disease (benign hepatic lesions, hemangiomas, biliary stones, and cholestatic jaundice). 76 In contrast, adverse liver effects are rare for oral estradiol, which has lower affinity for hepatic estrogen receptors relative to ethinyl estradiol, and for transdermal estradiol, which bypasses the enterohepatic circulation.
Breast milk production may be diminished by estrogens if administered before well-established lactation, which occurs at 6 to 8 weeks postpartum. In such situations, the reduction in milk supply is typically rapid (within a week after initiation; D. Bogen, MD, personal communication) and is characterized by increased infant crying between feeds, less satisfaction after feeding, fewer wet and soiled diapers and weight loss. Discontinuation of the exogenous estrogen treatment can often restore milk production. Extant data reveal negligible passage of estradiol into breast milk for doses up to 100 mcg/d. 51 Transdermal estradiol has not been widely tested nor has it been approved as a contraceptive. Investigators have demonstrated that transdermal estradiol 50 to 100 mcg/d treatment suppressed ovarian folliculogenesis and pituitary secretion of follicle stimulating hormone and luteinizing hormone 51, 59 ; however, additional study is warranted in larger samples and in nonlactating women.
Selection of a Progestogen to Be Used in Concert With Transdermal Estradiol for PPD Treatment
The administration of estradiol necessitates coadministration of a progestogen,
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which induces secretory transformation and shedding of the endometrial lining to protect against endometrial hyperplasia and cancer. Commonly used progestogens have oral, subcutaneous, or intrauterine administration. Intrauterine administration results in lower systemic progestogen absorption and thus potentially fewer side effects. Oral progestogens can be administered continuously or sequentially (every 3 mo). Similar to estrogens, not all progestogens are the same. The progestogen class is composed of diverse members that have in common the ability to induce secretory changes in the endometrium. Progesterone is the bioidentical hormone and dydrogesterone is the compound most like progesterone. The highly potent pregnane progestogens (ie, medroxyprogesterone acetate, megestrol, and cyproteron acetate) are synthetic derivatives of progesterone with modifications at the C-17 and C-6 sites. The synthetic 19-nortestosterone -derived group of progestogens is derived from testosterone and includes norethisterone, norgestrel, and desogestrel. The synthetic progestogens have come into widespread use due to ease of oral administration, ability to be prepared in parenteral, long-acting and depot formulations, and high progesterone receptor potency.
What Are the Risks of Progestin Treatment?
The mineralocorticoid activity of the progestogens is responsible for associated weight gain, bloating, and edema side effects. These effects are minimized with the antimineralocorticoid progestogen drospirenone. The 19-nortestosterone group possesses dermatologic side effects typical of androgens, including acne, greasy skin, and darkening of facial hair. These androgenic progestogens may also confer adverse metabolic effects including lowering of high density lipoprotein and decreased insulin sensitivity. 77 The pregnane and norpregnane derivatives are considered to have more intermediate effects on cardiovascular metabolic risk factors. The pregnane medroxyprogesterone acetate has been associated with vasospasm risk 78 and warrants additional study. Progesterone and dydrogesterone have the fewest associated adverse metabolic, vascular, and dermatologic effects relative to other progestogens.
Progestogen effects on mental health are variable. Endogenous progesterone metabolites (ie, allopregnanolone) are potent agonists of the g-aminobutyric acid type A receptor and thereby reduce anxiety and positively modulate mood. 79 Synthetic progestin components of hormonal contraceptives and hormone therapy have been alternatively associated with increased 63, [80] [81] [82] or decreased risk for depression 66, [82] [83] [84] [85] [86] [87] [88] [89] [90] In an RCT of postpartum healthy women assigned to the injectable progestin norethisterone enanthate (which is closely related to the progestin-only oral contraceptive commonly prescribed to lactating women) or placebo within 48 hours postdelivery, depression scores were higher in the progestin group at 6 weeks postpartum. 63 Progesterone itself, in contrast, has shown promise in the prophylaxis and/or treatment of PPD in several open studies, [83] [84] [85] and might be a preferred progestin for women with mood worsening during treatment with synthetic progestins. The levonorgestrel containing intrauterine device (Mirena) is an increasingly used contraceptive in postpartum women because of its low systemic absorption, convenience, tolerability, and cost-effectiveness. Continued study of cardiovascular and mental health effects of progestin compounds is needed.
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Conclusions
A convergence of epidemiologic, preclinical, and clinical research suggests the utility of transdermal estradiol for the treatment of PPD. Robust and rapid response to estradiol in 2 clinical PPD trials, few side effects, and minimal breast milk passage to the infant make estradiol a promising PPD treatment. Estradiol cannot be considered as a first-line agent among conventional antidepressant treatments for acute treatment of PPD until additional efficacy data are available. Additional safety data are also needed before estradiol can be considered as a treatment option for women who do not respond to or decline conventional treatments or who wish to use estradiol as an adjunct to conventional antidepressants. Outcomes related to maternal tolerability of cyclic progestins, long-term safety of high dose estradiol treatment, and high dose estradiol passage into breast milk and infants are of particular interest. The utility of continuation and maintenance treatment with estradiol has not been investigated with respect to PPD and warrants study. Lack of robust efficacy data of estradiol as a therapeutic for PPD has been the main obstacle for its clinical use. Studies to obtain this efficacy data in PPD have been challenged by the nonavailability of masked estradiol patches for use in RCTs. The Women's Health Initiative study also raised concerns about estrogen and progesterone-associated health risks that have discouraged additional study; however, such risks are minimal in young, reproductive-aged women. Another obstacle is the concern that estradiol could interfere with breast milk production, given the public health emphasis to increase lactation rates. A major obstacle is that estradiol treatment traditionally falls within the purview of obstetrics-gynecology whereas depression traditionally falls within the purview of psychiatry. Isolation of psychiatrists from obstetrical practitioners makes each clinician unfamiliar, inexperienced, and unwilling to assume full responsibility for estradiol treatment of PPD. As interdisciplinary practice of medicine grows, 92 models of interdisciplinary collaboration, such as colocation of Gynecology-Psychiatry clinics, will be poised to increase the application of hormonal treatments for mood disorders and to benefit the mental health of postpartum women.
